Plasma levels of neuropeptides in Alzheimer's disease

References

• Selkoe D J. The origins of Alzheimer disease: a is for amyloid. J Am Med Assoc 2000; 283: 1615–1617
   PubMed Web of Science ®Google Scholar
• Mattson M P, Pedersen W A. Effects of amyloid precursor protein derivatives and oxidative stress on basal forebrain cholinergic systems in Alzheimer's disease. Int J Dev Neurosci 1998; 16: 737–753
   PubMedGoogle Scholar
• Heilig M, Sjogren M, Blennow K, Ekman R, Wallin A. Cerebrospinal fluid neuropeptides in Alzheimer's disease ad vascular dementia. Biol Psychiatry 1995; 38: 210–216
   PubMedGoogle Scholar
• Gutniak M, Orskov C, Holst J J, Ahren B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7–36) in normal subjects and patients with diabetes mellitus. N Engl J Med 1992; 326: 1316–1322
   PubMed Web of Science ®Google Scholar
• Perfetti R, Zhou J, Doyle M E, Egan J M. Glucagon-like peptide-1 induces cell proliferation and pancreatic–duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000; 141: 4600–4605
   PubMed Web of Science ®Google Scholar
• Goke R, Larsen P J, Mikkelsen J D, Sheikh S P. Distribution of GLP-1 binding sites in the rat brain, evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 1995; 7: 2294–2300
   PubMed Web of Science ®Google Scholar
• Shughrue P J, Lane M V, Merchenthaler I. Glucagon-like peptide 1 receptor (GLP1-R) mRNA in the rat hypothalamus. Endocrinology 1996; 137: 5159–5162
   PubMed Web of Science ®Google Scholar
• Satoh F, Beak S A, Small C J, Falzon M, Ghatei M A, Bloom S R, Smith D M. Characterization of human and rat glucagon-like peptide-1 receptors in the neurointermediate lobe, lack of coupling to either stimulation or inhibition of adenyl cyclase. Endocrinology 2000; 141: 1301–1309
   PubMedGoogle Scholar
• Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-1, brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995; 358: 219–224
   PubMed Web of Science ®Google Scholar
• Perry T, Lahiri D K, Sambamurti K, Chen D, Mattson M P, Egan J M, Greig N H. Glucagon-like peptide-1 decreases endogenous amyloid-β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron. J Neurosci Res 2003; 72: 603–612
   PubMed Web of Science ®Google Scholar
• Mattson M P, Lovell M A, Furukawa K, Markesbery W R. Neurotrophic factors attenuate glutamate-induced accumulation of peroxides, elevation of intracellular Ca2 + concentration, and neurotoxicity and increase antioxidant enzyme activities in hippocampal neurons. J Neurochem 1995; 65: 1740–1751
   PubMed Web of Science ®Google Scholar
• Magni P. Hormonal control of the neuropeptide Y system. Curr Protein Pept Sci 2003; 4: 45–57
   PubMedGoogle Scholar
• Ekman R, Juhasz P, Heilig M, Agren H, Costello C E. Novel neuropeptide Y processing in human cerebrospinal fluid from depressed patients. Peptides 1996; 17: 1107–1111
   PubMedGoogle Scholar
• Zukowska-Grojec Z, Neuropeptide Y. A novel sympathetic stress hormone and more. Ann N Y Acad Sci 1995; 771: 219–233
   PubMed Web of Science ®Google Scholar
• Nakagawara M, Sato Y. Neuropeptide Y: psychopharmacological and clinical aspects. Nihon Shinkei Seishin Yakurigaku Zasshi 1994; 14: 117–127
   PubMedGoogle Scholar
• Kojima M, Hosada H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 565–560
   PubMedGoogle Scholar
• Tschop M, Smiley D L, Heiman M L. Ghrelin induces adiposity in rodents. Nature 2000; 407: 908–913
   PubMed Web of Science ®Google Scholar
• Creyghton W M, van Dam P S, Koppeschaar H P. The role of somatotropic system in cognition and other cerebral functions. Semin Vasc Med 2004; 4: 167–172
   PubMedGoogle Scholar
• Morley J E. Anorexia of aging: physiologic and pathologic. Am J Clin Nutr 1997; 66: 760–773
   PubMed Web of Science ®Google Scholar
• Morley J E. Anorexia, sarcopenia, and aging. Nutrition 2001; 17: 660–663
   PubMed Web of Science ®Google Scholar
• Rigamonti A E, Pincelli A I, Corra B, Viarengo R, Bonomo S M, Galimberti D, Scacchi M, Scarpini E, Cavagnini F, Muller E E. Plasma ghrelin concentration in elderly subjects: comparison with anorexic and obese patients. J Endocrinol 2002; 175: R1–R5
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. APA Press, Washington, DC 1994
   Google Scholar
• Hachinski V C, Iliff L D, Zilhka E, Du Boulay G H, McAllister V L, Marshall J, Russell R W, Symon L. Cerebral blood flow in dementia. Arch Neurol 1975; 32: 632–637
   PubMed Web of Science ®Google Scholar
• Folstein M F, Folstein S E, McHugh P R. ‘Mini-Mental State’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–198
   PubMed Web of Science ®Google Scholar
• Katz S, Ford A B, Moskowitz R W, Jackson B A, Jaffe M W. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial functions. J Am Med Assoc 1963; 185: 914–919
   PubMed Web of Science ®Google Scholar
• Lawton M P, Brody E M. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 179–186
   PubMed Web of Science ®Google Scholar
• Brazzelli M, Capitani E, Della Sala E, Spinnler H, Zuffi M. A neuropsychological instrument adding to description of patients with suspected cortical dementia: the Milan overall dementia assessment. J Neurol Neurosurg Psychiatry 1994; 57: 1510–1517
   PubMed Web of Science ®Google Scholar
• Rey A. Memorisation d'un serie de 15 mots en 5 repetition. l'Examen clinique en psychologie., A Rey. Presses Universitaires de France, Paris 1958; 141–193
   Google Scholar
• Raven J C. Guide to using the coloured progressive matrices. Revised ed. HK Lewis, London 1956
   Google Scholar
• De Renzi E, Nichelli P. Verbal and nonverbal short-term memory impairment following hemispheric damage. Cortex 1975; 11: 341–353
   PubMedGoogle Scholar
• Brink T L, Yesavage J A, Lum O, Heersema P H, Adey M, Rose T L. Screening test for geriatric depression. Clin Gerontol 1982; 1: 37–43
   Google Scholar
• Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278–296
   PubMed Web of Science ®Google Scholar
• Reisberg B, Ferris S H, De Leon M J, Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139: 1136–1139
   PubMed Web of Science ®Google Scholar
• Guigoz Y, Vellas B, Garry P J. Mini Nutritional Assessment: a practical assessment tool for grading the nutritional state of elderly patients. Facts Res Gerontol 1994; 4(Suppl 2)15–59
   Google Scholar
• Calvo J C, Yusata B, Mora F, Blazquez E. Structural characterization by affinity cross-linking of glucagon-like peptide-1 (7–36) amide receptor in rat brain. J Neurochem 1995; 64: 299–306
   PubMedGoogle Scholar
• Campos R V, Lee Y C, Drucker D J. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 1994; 134: 2156–2164
   PubMed Web of Science ®Google Scholar
• Perry T, Haughey N J, Mattson M P, Egan J M, Greig N H. Protection and reversal of excitotoxic neuronal damage by glucagons-like peptide-1 and exendin-4. J Pharmacol Exp Ther 2002; 302: 881–888
   PubMed Web of Science ®Google Scholar
• Mattson M P. Cellular actions of β-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev 1997; 77: 1081–1132
   PubMed Web of Science ®Google Scholar
• Perry T A, Greig N H. A new Alzheimer's disease interventive strategy: GLP-1. Curr Drug Targets 2004; 5: 565–571
   PubMed Web of Science ®Google Scholar
• Atack J R, Beal M F, May C, Kaye J A, Mazurek M F, Kay A D, Rapoport S I. Cerebrospinal fluid somatostatin and neuropeptide Y. Concentration in aging and in dementia of the Alzheimer type with and without extrapyramidal signs. Arch Neurol 1988; 45: 269–274
   PubMedGoogle Scholar
• Beal M F, Kowall N W, Mazurek M F. Neuropeptides in Alzheimer's disease. J Neural Transm Suppl 1987; 24: 163–174
   PubMedGoogle Scholar
• Gabriel S M, Bierer L M, Harotunian V, Purohit D P, Perl D P, Davis K L. Widespread deficits in somatostatin but not neuropeptide Y concentration in Alzheimer's disease cerebral cortex. Neurosci Lett 1993; 155: 116–120
   PubMedGoogle Scholar
• Alom J, Galard R, Cataslan R, Castellanos J M, Schwartz S, Tolosa E. Cerebrospinal fluid neuropeptide Y in Alzheimer's disease. Neurosci Lett 1995; 198: 1549–1551
   Google Scholar
• Edvinsson L, Minthon L, Ekman R, Gustafson L. Neuropeptides in cerebrospinal fluid of patients with Alzheimer's disease and dementia with frontotemporal lobe degeneration. Dementia 1993; 4: 167–171
   PubMedGoogle Scholar
• Nordberg A. Neuroreceptor changes in Alzheimer disease. Cerebrovasc Brain Metab Rev 1992; 4: 303–328
   PubMedGoogle Scholar
• Koide S, Onishi H, Hashimoto H, Kai T, Yamagami S. Plasma neuropeptide Y is reduced in patients with Alzheimer's disease. Neurosci Lett 1995; 198: 149–151
   PubMedGoogle Scholar
• Hellstrom P M, Geliebter A, Naslund E, Schmidt P T, Yahav E K, Hashim S A, Yeomans M R. Peripheral and central signals in the control of eating in normal, obese and binge-eating human subjects. Br J Nutr 2004; 92(Suppl 1)S47–S57
   Google Scholar
• Chapman I M. Endocrinology of anorexia of aging. Best Pract Res Clin Endocrinol Metab 2004; 18: 437–452
   PubMed Web of Science ®Google Scholar
• Gillette-Guyonnet S, Nourhashemi F, Andrieu S, de Glisezinski I, Ousset P J, Riviere D, Albarede J L, Vellas B. Weight loss in Alzheimer disease. Am J Clin Nutr 2000; 71: 637S–642S
   PubMed Web of Science ®Google Scholar